Santaris Pharma and Wyeth Pharmaceuticals, announced January 12th 2009 that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) drug platform.
Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in Santaris Pharma. Santaris Pharma may receive further milestone payments of up to $83 million for each of 10 potential targets. In addition, Santaris Pharma would receive royalties on the worldwide sales of all products arising from the alliance.
Sunstone Capital portfolio company Zealand Pharma A/S and Helsinn Healthcare SA today announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting patients undergoing cancer treatment with a range of chemotherapies.
NatImmune A/S today announced the initiation of a phase IIb clinical trial designed to evaluate the safety and efficacy of its BAMLET Tropical Gel, a protein-lipid based proprietary dermatological product candidate, for the treatment of recalcitrant warts in immuno-suppressed kidney-transplanted patient when applied locally to wart lesions.
Copenhagen, Denmark and Seattle, WA, USA, June 19, 2008—ACE BioSciences and PATH have announced a new partnership to advance the development of a promising vaccine against one of the leading bacterial causes of diarrheal disease, enterotoxigenic E.coli (ETEC). PATH will fund ACE BioSciences to complete Phase 1 and Phase 2 clinical trials up to proof of concept of its ACE527 vaccine. ACE527 offers the broadest coverage among currently available ETEC vaccine formulations, and the vaccine’s components have already been tested in more than 100 subjects.
Sunstone Capital A/S announces the Second Closing of its fundraising that began in 2007. New investors include institutional investors Sampension Private Equity F.M.B.A. and Finnish Industry Investment Ltd, as well as additional private investors, who in total have committed approximately EUR 21 million, increasing total funds under management to EUR 411 million.